HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Qinglian Li Selected Research

morpholinoanthracycline MX2 (MX-2)

5/2016Improving the N-terminal diversity of sansanmycin through mutasynthesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Qinglian Li Research Topics

Disease

1Ischemic Stroke
12/2021
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
12/2021
1Essential Hypertension
04/2021
1Unstable Angina
04/2021
1Neoplasms (Cancer)
01/2018
1Infections
10/2017
1Tuberculosis (Tuberculoses)
05/2016
1Asthma (Bronchial Asthma)
10/2002

Drug/Important Bio-Agent (IBA)

3Pharmaceutical PreparationsIBA
12/2021 - 05/2016
13-n-butylphthalide (butylphthalide)IBA
12/2021
1Sodium CholateIBA
12/2021
1Liposomes (Liposome)IBA
12/2021
1HDL LipoproteinsIBA
04/2021
1TransferasesIBA
04/2021
1borrelidinIBA
01/2018
1StreptograminsIBA
10/2017
1griseoviridinIBA
10/2017
1Anti-Bacterial Agents (Antibiotics)IBA
10/2017
1etamycinIBA
10/2017
1sansanmycinIBA
05/2016
1morpholinoanthracycline MX2 (MX-2)IBA
05/2016

Therapy/Procedure

2Therapeutics
12/2021 - 10/2002